Showing results (81-90 of 128) with videos related to
Sort By:
Pageof 13
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.BMC Cancer|April 22, 2021
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancersKristin L Ayers, Meng Ma, Gaspard Debussche, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2013
Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapyMartin K H Maus, Philip C Mack, Stephanie H Astrow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Roy S Herbst, Karen Kelly, Kari Chansky, et al.Clinical Lung Cancer|January 29, 2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trialPrimo N Lara, Jeff Longmate, Karen Reckamp, et al.Frontiers in Oncology|March 28, 2019
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)Karen L Reckamp, Paul H Frankel, Nora Ruel, et al.Cancer Chemotherapy and Pharmacology|January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerRamesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.The Oncologist|March 17, 2022
Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung AdenocarcinomaPhilip C Mack, Michael I Klein, Kristin L Ayers, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Charu Aggarwal, Mary W Redman, Primo N Lara, et al.Pageof 13